Systematic PSA-based screening for prostate cancer remains controversial due to the trade-off between reduced mortality and risk of overdiagnosis and overtreatment. Adding new tools like magnetic-resonance-imaging-targeted biopsies and genetic markers may limi... ...

请注册登录后继续浏览